Vancomycin-resistant enterococci and use of avoparcin in animal feed: is there a link?

---

• 1.
• VRE are present in animals receiving avoparcin;

• 2.
• VRE are more common in animals, farm areas and countries where avoparcin has been used (and rare or absent in areas where it has not been used);

• 3.
• VRE are detectable in food products from animals fed avoparcin; and

• 4.
• VRE are found in the general community in people who have, or are likely to have, consumed these products.
• 5.
• Collignon P. Antibiotic resistance: is it leading to the re-emergence of many infections from the past? In: Asche V, editor. Recent advances in microbiology. Vol 5. Melbourne: Australian Society for Microbiology, 1997: 203-256.
• 6.
• Turnidge J, Howard R. Australia's antibiotic burden. Microbiol Aust 1996; 17: 11.
• 7.
• Roche Products. Product information for Avotan 100, feed supplement (active constituent: avoparcin 100g/kg). National Registration Authority for Agricultural and Veterinary Chemicals approval no. 45710/01. Sydney: Roche Products.
• 8.
• French GL. Enteroccoci and vancomycin resistance. Clin Infect Dis 1998; 27 Suppl 1: S75-S83.
• 9.
• Collignon PJ, Bell JM, on behalf of the Australian Group on Antimicrobial Resistance. Drug-resistant Streptococcus pneumoniae: the beginning of the end for many antibiotics? Med J Aust 1996; 164: 64-67.
• 10.
• Swedish Commission on Antimicrobial Feed Additives. Antimicrobial feed additives. Stockholm: Ministry of Agriculture, 1997.
• 11.
• Witte W. Impact of antibiotic use in animal feeding on resistance of bacterial pathogens in humans. Ciba Found Symp 1997; 207: 61-75.
• 12.
• Wegener HC, Aarestrup FM, Bogo Jensen L, et al. Use of antimicrobial growth promoters in food animals and Enterococcus faecium resistance to therapeutic antimicrobial drugs in Europe. Emerg Infect Dis 1999; 5: 329-335.
• 13.
• McDonald LC, Kuehnert MJ, Tenover FC, Jarvis WR. Vancomycin-resistant enterococci outside the health-care setting: prevalence, sources, and public health implications. Emerg Infect Dis 1997; 3: 311-317.
• 14.
• Van den Braak N, van Belkum A, van Keulen M, et al. Molecular characterization of vancomycin-resistant enterococci from hospitalized patients and poultry products in the Netherlands. J Clin Microbiol 1998; 36: 1927-1932.
• 15.
• Noble W, Virani Z, Cree R. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992; 72: 195-198.
• 16.
• Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-136.
• 17.
• Paterson D. Reduced susceptibility of Staphylococcus aureus to vancomycin -- a review of current knowledge. Commun Dis Intell 1999; 24: 69-73.
• 18.
• Edmond MB, Ober JF, Dawson JD, et al. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996; 23: 1234-1239.
• 19.
• Das I, Fraise A, Wise R. Are glycopeptide-resistant enterococci in animals a threat to human beings? Lancet 1997; 349: 997-998.
• 20.
• Doll R, Peto R. Mortality in relation to smoking: 20 years' observation on male British doctors. BMJ 1976; 2: 1525-1536.
• 21.
• Klein G, Pack A, Reuter G. Antibiotic resistance patterns of enterococci and occurrence of vancomycin-resistant enterococci in raw minced beef and pork in Germany. Appl Environ Microbiol 1998; 64: 1825-1830.
• 22.
• Van der Auwera P, Pensart N, Korten V, et al. Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci. J Infect Dis 1996; 173: 1129-1136.
• 23.
• Jensen LB. Differences in the occurrence of two base pair variants of Tn1546 from vancomycin-resistant enterococci from humans, pigs, and poultry. Antimicrob Agents Chemother 1998; 42: 2463-2464.
• 24.
• Schoonmaker D, Bopp L, Baltch A, et al. Genetic analysis of multiple vancomycin-resistant Enterococcus isolates obtained serially from two long-term-care patients. J Clin Microbiol 1998; 36: 2105-2108.
• 25.
• Zervos M, Bacon A, Patterson J, et al. Enterococcal superinfection in patients treated with ciprofloxacin. J Antimicrob Chemother 1988; 21: 113-115.
• 26.
• Moellering R. Enterococcal infections in patients treated with moxalactam. Rev Infect Dis 1982; 4 Suppl: S708-S711.
• 27.
• Kirst H, Thompson D, Nicas T. Historical yearly usage of vancomycin. Antimicrob Agents Chemother 1998; 42: 1303-1304.
• 28.
• Witte W. Medical consequences of antibiotic use in agriculture. Science 1998; 279: 996-997.
• 29.
• Allerberger F, Lass-Florl C, Dierich MP, et al. Vancomycin resistant enterococci in Austria. [Original title: Vancomycin resistente Enterokokken in Osterreich.] Wien Klin Wochenschr 1997; 109: 312-320.
• 30.
• Bell J, Turnidge J, Coombs G, O'Brien F. Emergence and epidemiology of vancomycin-resistant enterococci in Australia. Commun Dis Intell 1998; 22: 249-252.
• 31.
• Butt H, Bell J, Ferguson J. Are vancomycin-resistant enterococci prevalent in Hunter region farm animals? Abstracts of the Australian Society for Microbiology Annual Conference; 1997 29 Sep - 3 Oct; Adelaide, SA. Microbiol Aust 1997; 18(4): abstract PO4.8.
• 32.
• Joint Committee of Houses of Parliament. Report on the use of antibiotics in animal husbandry and veterinary medicine ("Swann Report"). London: HMSO, 1969, reprinted 1971.